

Michigan Pharmacy and Therapeutics Committee (P and T)
Diabetes Workgroup
July 2007

Following review and discussion, the workgroup recommends to the full P and T Committee for review at the September meeting the following regarding the Diabetes classes in the Preferred Drug List:

Amylin Analogs

No change to current classification

Secretin Mimetics

No change to current classification

Insulins, Basal

No change to current classification

Insulins, Rapid Acting

No change to current classification

Insulin Mixes

No change to current classification

Insulins, Traditional

No change to current classification

Insulins, Inhaled

No change to current classification

Oral Hypoglycemics-Alpha Glucosidase Inhibitors

No change to current classification

Oral Hypoglycemics-Biguanides

No change to current classification

Remove prior authorization from the 750mg strength Metformin XR on the Michigan Pharmaceutical Product List

Oral Hypoglycemics-Combinations

No change to current classification

Oral Hypoglycemics-DPP4 Inhibitors

No change to current classification

Oral Hypoglycemics-Meglitinides

No change to current classification

Oral Hypoglycemics-2nd Generation Sulfonylureas

No change to current classification

Oral Hypoglycemics-Thiazolidinediones

No change to current classification at this time; the workgroup will closely monitor any further clarification from the FDA.